- ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealFor years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…Fierce Biotech · 6d ago↗ source
- Broad Institute launches Center for Therapeutic Genetics for rare diseasesThe Broad Institute of MIT and Harvard is teaming up with Boston Children’s Hospital and The Jackson Laboratory to launch a new center focused on genetic treatments for rare diseases, the triumvira…Endpoints · 6d ago↗ source
- STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environmentAmbient scribe developer Nabla said Brian Manning will be the Paris-based company's new CEO as it looks to grow in a highly competitive market.